Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

(2018) Jennifer Tsoi et al.   CANCER CELL

Rituximab as a therapeutic option for patients with advanced melanoma

(2018) Julia K. Winkler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

(2018) Theodore S. Nowicki et al.   CANCER JOURNAL

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

(2018) Sara Valpione et al.   EUROPEAN JOURNAL OF CANCER

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway

(2018) Xuerong Sun et al.   Cell Death & Disease

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

(2018) Arnav Mehta et al.   Cancer Discovery

Abstract CT176: Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors

(2018) John M. Kirkwood et al.   CANCER RESEARCH

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma

(2017) Paola Falletta et al.   GENES & DEVELOPMENT

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy

(2017) Cristina Maccalli et al.   IMMUNOLOGICAL INVESTIGATIONS

Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?

(2017) Constance E. Brinckerhoff   JOURNAL OF CELLULAR PHYSIOLOGY

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

(2017) Helen L. Young et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Recent Advances in Melanoma and Melanocyte Biology

(2017) Hensin Tsao et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Notch3 signaling-mediated melanoma–endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis

(2017) Mei-Yu Hsu et al.   LABORATORY INVESTIGATION

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma

(2017) Dhiraj Kumar et al.   Molecular Cancer

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

(2017) Mohammad Fallahi‐Sichani et al.   Molecular Systems Biology

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

(2017) Xiangjun Kong et al.   NATURE

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

(2017) Thomas Kammertoens et al.   NATURE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Tumour heterogeneity and resistance to cancer therapies

(2017) Ibiayi Dagogo-Jack et al.   Nature Reviews Clinical Oncology

Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells

(2017) Yash Chhabra et al.   Pigment Cell & Melanoma Research

Interferon-γ is a master checkpoint regulator of cytokine-induced differentiation

(2017) Zhao Zha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

(2017) Yapeng Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clonal cooperativity in heterogenous cancers

(2017) Hengbo Zhou et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

(2017) Rajasekharan Somasundaram et al.   Nature Communications

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

(2017) Antje Sucker et al.   Nature Communications

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

(2017) Chunying Song et al.   Cancer Discovery

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

(2017) Daniel Zingg et al.   Cell Reports

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF

(2017) Mitchell E. Fane et al.   EBioMedicine

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

(2016) Michael P. Smith et al.   CANCER CELL

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

(2016) Andy J. Minn et al.   CELL

Persistence to anti-cancer treatments in the stationary to proliferating transition

(2016) Sivan Pearl Mizrahi et al.   CELL CYCLE

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

(2016) A. A. N. Rose et al.   CLINICAL CANCER RESEARCH

Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness

(2016) Njainday Pulo Jobe et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition

(2016) Ritin Sharma et al.   JOURNAL OF PROTEOME RESEARCH

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Both Complexity and Location of DNA Damage Contribute to Cellular Senescence Induced by Ionizing Radiation

(2016) Xurui Zhang et al.   PLoS One

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

(2016) Stefani Spranger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

(2016) Chengguang Zhao et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

(2016) Bjoern Titz et al.   Cell Discovery

Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me’

(2015) A O Pisco et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

(2015) T. Wang et al.   CLINICAL CANCER RESEARCH

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

(2015) M. P. Mak et al.   CLINICAL CANCER RESEARCH

Metastatic Melanoma Cells Evade Immune Detection by Silencing STAT1

(2015) JoDi Osborn et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Paeonol inhibits B16F10 melanoma metastasisIn vitroandIn Vivovia disrupting proinflammatory cytokines-mediated NF-κB and STAT3 pathways

(2015) Lei Zhang et al.   IUBMB LIFE

Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy

(2015) Chien-Chung Chang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

(2015) Inna V. Fedorenko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

(2015) Martin Lauss et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

MITF Modulates Therapeutic Resistance through EGFR Signaling

(2015) Zhenyu Ji et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cancer Microenvironment and Endoplasmic Reticulum Stress Response

(2015) Claudia Giampietri et al.   MEDIATORS OF INFLAMMATION

Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma

(2015) Oren Litvin et al.   MOLECULAR CELL

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy

(2015) Claudia Wellbrock et al.   Pigment Cell & Melanoma Research

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

Cancer and the Immune System: Basic Concepts and Targets for Intervention

(2015) Drew Pardoll   SEMINARS IN ONCOLOGY

Interferons and the Immunogenic Effects of Cancer Therapy

(2015) Andy J. Minn   TRENDS IN IMMUNOLOGY

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment

(2015) Stefanie Riesenberg et al.   Nature Communications

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

(2015) Hyungsoo Kim et al.   Cell Reports

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

(2015) Rachel Ramsdale et al.   Science Signaling

The mutually regulatory loop of epithelial–mesenchymal transition and immunosuppression in cancer progression

(2015) Limo Chen et al.   OncoImmunology

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

(2015) Jennifer A. Lo et al.   JAMA Oncology

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

(2015) Mickaël Ohanna et al.   Oncotarget

The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways

(2014) A. Slominski et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

(2014) K. Kemper et al.   CANCER RESEARCH

Cellular Differences in Protein Synthesis Regulate Tissue Homeostasis

(2014) Michael Buszczak et al.   CELL

MITF in melanoma: mechanisms behind its expression and activity

(2014) Mariusz L. Hartman et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression

(2014) A. Sucker et al.   CLINICAL CANCER RESEARCH

UV Signaling Pathways within the Skin

(2014) Hongxiang Chen et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement

(2014) M Bardini et al.   LEUKEMIA

Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta12,14-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway

(2014) Su-Kil Seo et al.   LIFE SCIENCES

Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients

(2014) Cornelia G.F. van Lanschot et al.   MELANOMA RESEARCH

PhiC31/PiggyBac modified stromal stem cells: effect of interferon γ and/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on murine melanoma

(2014) Vahid Bahrambeigi et al.   Molecular Cancer

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers

(2014) Allison S. Cleary et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

A stress-induced early innate response causes multidrug tolerance in melanoma

(2014) D Ravindran Menon et al.   ONCOGENE

Cyclin-dependent kinases as therapeutic targets in melanoma

(2014) David M. Miller et al.   Pigment Cell & Melanoma Research

Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells

(2014) Marie R. Webster et al.   Pigment Cell & Melanoma Research

IFN-γ signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation

(2014) Vivek T. Natarajan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases

(2014) Joël P. Charles et al.   Nature Communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFN -Dependent Cell-Cycle Arrest

(2014) H. Matsushita et al.   Cancer Immunology Research

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes

(2013) D Murtas et al.   BRITISH JOURNAL OF CANCER

Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells

(2013) Sui Huang   CANCER AND METASTASIS REVIEWS

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

MITF, the Janus transcription factor of melanoma

(2013) Dana Koludrovic et al.   Future Oncology

Vemurafenib Induces Senescence Features in Melanoma Cells

(2013) Sebastian Haferkamp et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Stem cells and targeted approaches to melanoma cure

(2013) George F. Murphy et al.   MOLECULAR ASPECTS OF MEDICINE

T-helper-1-cell cytokines drive cancer into senescence

(2013) Heidi Braumüller et al.   NATURE

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Tumor metastasis: moving new biological insights into the clinic

(2013) Liling Wan et al.   NATURE MEDICINE

Hypoxia-induced senescence contributes to the regulation of microenvironment in melanomas

(2013) Jing Mo et al.   PATHOLOGY RESEARCH AND PRACTICE

Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1

(2013) Jonathan T. Sims et al.   PLoS One

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

How to escape the cancer attractor: Rationale and limitations of multi-target drugs

(2013) Sui Huang et al.   SEMINARS IN CANCER BIOLOGY

Non-Darwinian dynamics in therapy-induced cancer drug resistance

(2013) Angela Oliveira Pisco et al.   Nature Communications

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Cancer Stem Cells: Distinct Entities or Dynamically Regulated Phenotypes?

(2012) Y. Li et al.   CANCER RESEARCH

Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells

(2012) Martina J Schmitt et al.   Cell Communication and Signaling

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence

(2012) Yan Liu et al.   EMBO Molecular Medicine

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

(2012) Michael P. Smith et al.   JNCI-Journal of the National Cancer Institute

Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells

(2012) Sangkil Nam et al.   Molecular Oncology

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Stochastic expression dynamics of a transcription factor revealed by single-molecule noise analysis

(2012) Zach Hensel et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic classification of melanoma cells by phenotype-specific gene expression mapping

(2012) Daniel S. Widmer et al.   Pigment Cell & Melanoma Research

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Nonheritable Cellular Variability Accelerates the Evolutionary Processes of Cancer

(2012) Steven A. Frank et al.   PLOS BIOLOGY

Senescent Cells in Growing Tumors: Population Dynamics and Cancer Stem Cells

(2012) Caterina A. M. La Porta et al.   PLoS Computational Biology

A Requirement of STAT3 DNA Binding Precludes Th-1 Immunostimulatory Gene Expression by NF- B in Tumors

(2011) H. Lee et al.   CANCER RESEARCH

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival

(2011) Jonathan R. Brody et al.   CELL CYCLE

Association of IFN-  Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

(2011) A. Respa et al.   CLINICAL CANCER RESEARCH

The Two Faces of Interferon-  in Cancer

(2011) M. R. Zaidi et al.   CLINICAL CANCER RESEARCH

Senescent cells develop a PARP-1 and nuclear factor- B-associated secretome (PNAS)

(2011) M. Ohanna et al.   GENES & DEVELOPMENT

MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis

(2011) P. Hemon et al.   JOURNAL OF IMMUNOLOGY

Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance

(2011) Edward H. Flach et al.   MOLECULAR PHARMACEUTICS

Interferon-γ links ultraviolet radiation to melanomagenesis in mice

(2011) M. Raza Zaidi et al.   NATURE

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

(2011) Satoru Yokoyama et al.   NATURE

A novel steroidal inhibitor of estrogen-related receptor α (ERRα)

(2010) Sarah J. Duellman et al.   BIOCHEMICAL PHARMACOLOGY

Interferon   limits the effectiveness of melanoma peptide vaccines

(2010) H.-I. Cho et al.   BLOOD

Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells

(2010) Gregory B Lesinski et al.   BMC CANCER

Microphthalmia-Associated Transcription Factor Controls the DNA Damage Response and a Lineage-Specific Senescence Program in Melanomas

(2010) Sandy Giuliano et al.   CANCER RESEARCH

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Cellular Heterogeneity: Do Differences Make a Difference?

(2010) Steven J. Altschuler et al.   CELL

Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth

(2010) Julia Schultz et al.   CLINICAL & EXPERIMENTAL METASTASIS

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

(2010) Heehyoung Lee et al.   NATURE MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lighting a path to pigmentation: mechanisms of MITF induction by UV

(2010) Jue J. Liu et al.   Pigment Cell & Melanoma Research

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

(2010) Marie C. Zipser et al.   Pigment Cell & Melanoma Research

Identification and targeting of cancer stem cells

(2009) Tobias Schatton et al.   BIOESSAYS

Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors

(2009) Heehyoung Lee et al.   CANCER CELL

Non-genetic cell-to-cell variability and the consequences for pharmacology

(2009) Mario Niepel et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis

(2009) Sabrina L. Spencer et al.   NATURE

Cancer stem cells: mirage or reality?

(2009) Piyush B Gupta et al.   NATURE MEDICINE

Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours

(2009) Amy Brock et al.   NATURE REVIEWS GENETICS

Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective

(2009) Sui Huang et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Molecular Basis for the Critical Role of Suppressor of Cytokine Signaling-1 in Melanoma Brain Metastasis

(2008) F.-J. Huang et al.   CANCER RESEARCH

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences

(2008) Arjun Raj et al.   CELL

Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence

(2008) Juan C. Acosta et al.   CELL

Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack

(2008) Gal Markel et al.   IMMUNOLOGY

Melanoma Stem Cells: The Dark Seed of Melanoma

(2008) Susan E. Zabierowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of cells initiating human melanomas

(2008) Tobias Schatton et al.   NATURE

Efficient tumour formation by single human melanoma cells

(2008) Elsa Quintana et al.   NATURE

Stochasticity and Cell Fate

(2008) R. Losick et al.   SCIENCE

Dynamic Proteomics of Individual Cancer Cells in Response to a Drug

(2008) A. A. Cohen et al.   SCIENCE